ASPP2κ Is Expressed In Human Colorectal Carcinoma And Promotes Chemotherapy Resistance And Tumorigenesis.
ASPP2
ASPP2κ
TP53
alternative splicing
apoptosis
colon cancer
therapy resistance
tumorigenesis
Journal
Frontiers in molecular biosciences
ISSN: 2296-889X
Titre abrégé: Front Mol Biosci
Pays: Switzerland
ID NLM: 101653173
Informations de publication
Date de publication:
2021
2021
Historique:
received:
18
06
2021
accepted:
14
10
2021
entrez:
22
11
2021
pubmed:
23
11
2021
medline:
23
11
2021
Statut:
epublish
Résumé
Alternative splicing is a common physiologic mechanism to generate numerous distinct gene products from one gene locus, which can result in unique gene products with differing important functional outcomes depending on cell context. Aberrant alternative splicing is a hallmark of cancer that can contribute to oncogenesis and aggressiveness of the disease as well as resistance to therapy. However, aberrant splicing might also result in novel targets for cancer therapy. ASPP2 is a haplo-insufficient tumor suppressor, that functions through both p53-dependent as well as p53-independent mechanisms to enhance cell death after stress. Interestingly, the common human tumor
Identifiants
pubmed: 34805267
doi: 10.3389/fmolb.2021.727203
pii: 727203
pmc: PMC8602356
doi:
Types de publication
Journal Article
Langues
eng
Pagination
727203Informations de copyright
Copyright © 2021 Rieger, Tsintari, Overkamp, Fend, Lopez, Schittenhelm and Kampa-Schittenhelm.
Déclaration de conflit d'intérêts
MS and KK-S hold patents U.S. 13/753,354, PCT/EP 2011/063283, and GER 102010033575.4–41. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Oncol Lett. 2018 May;15(5):6409-6417
pubmed: 29731851
Mol Cancer. 2015 Oct 05;14:177
pubmed: 26438046
Nat Rev Clin Oncol. 2020 Jan;17(1):11-32
pubmed: 31289352
Cell Cycle. 2006 Oct;5(19):2187-90
pubmed: 16969108
Science. 2013 Mar 29;339(6127):1546-58
pubmed: 23539594
Oncogene. 2009 May 21;28(20):2065-73
pubmed: 19377511
J Biol Chem. 2004 Jul 30;279(31):32046-54
pubmed: 15161933
Nat Rev Gastroenterol Hepatol. 2019 Jun;16(6):361-375
pubmed: 30886395
Biochem Biophys Res Commun. 2004 Mar 5;315(2):434-8
pubmed: 14766226
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Rev Cancer. 2017 Feb;17(2):79-92
pubmed: 28050011
Mol Cell Biol. 2004 Feb;24(3):1341-50
pubmed: 14729977
Mol Cell. 2001 Oct;8(4):781-94
pubmed: 11684014
Genes Cells. 2005 Mar;10(3):253-60
pubmed: 15743414
FEBS Lett. 1995 Dec 27;377(3):295-300
pubmed: 8549741
Genes Cells. 2005 Aug;10(8):803-11
pubmed: 16098144
Nat Rev Cancer. 2006 Mar;6(3):217-26
pubmed: 16498444
J Biol Chem. 2009 May 15;284(20):13812-13822
pubmed: 19246451
Br J Cancer. 2007 Jan 29;96(2):196-200
pubmed: 17211478
Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4390-5
pubmed: 19251665
Cell. 1990 Jun 1;61(5):759-67
pubmed: 2188735
Leuk Lymphoma. 2002 Dec;43(12):2309-17
pubmed: 12613517
Br J Haematol. 2000 Sep;110(3):563-72
pubmed: 10997965
Carcinogenesis. 2013 Sep;34(9):2170-7
pubmed: 23671128
EBioMedicine. 2019 Apr;42:340-351
pubmed: 30952616
J Gastrointest Cancer. 2021 Mar;52(1):169-176
pubmed: 32086781
J Biol Chem. 2007 Dec 28;282(52):37747-58
pubmed: 17965023
Science. 1996 Nov 8;274(5289):1001-5
pubmed: 8875926
Mol Cell Biol. 1996 Jul;16(7):3884-92
pubmed: 8668206
Nat Genet. 2006 Oct;38(10):1133-41
pubmed: 16964264
J Biol Chem. 1998 Oct 2;273(40):26061-8
pubmed: 9748285
Cell Cycle. 2009 Sep 15;8(18):2871-6
pubmed: 19657229
Biochem Biophys Res Commun. 2017 Jan 22;482(4):1271-1277
pubmed: 27939881
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):312-7
pubmed: 23248303
J Neurochem. 2003 May;85(3):801-9
pubmed: 12694406
PLoS One. 2013 Nov 27;8(11):e80193
pubmed: 24312201
Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6098-102
pubmed: 8016121